Omega Advisors’s Blueprint Medicines BPMC Stock Holding History

Omega Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-75,000	Closed	-$5.66M	–	88
2017 Q4	$5.66M	Buy	+75,000	New	+$5.28M	0.21%	57

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Omega Advisors's BPMC Position: Q1 2018 in Review

Omega Advisors sold out of Blueprint Medicines (BPMC) in Q1 2018, closing a stake of 75,000 shares — an estimated $5.66M sold.

Omega Advisors first reported a position in BPMC in Q4 2017 and held it in 1 quarter. The position peaked at $5.66M in Q4 2017. 175 funds tracked by Wall St. Rank hold BPMC as of Q1 2018.

Omega Advisors reported no remaining Blueprint Medicines position as of Q1 2018 after selling out during the quarter.
Omega Advisors sold 75,000 Blueprint Medicines shares in Q1 2018, an estimated $5.66M.
Omega Advisors first reported a position in Blueprint Medicines in Q4 2017 and held it in 1 quarter.
Omega Advisors's Blueprint Medicines position peaked at $5.66M in Q4 2017.
175 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2018.

Based on Omega Advisors's 13F filing for Q1 2018, filed 15 May 2018.